Redirecting to https://pr.stylemg.com/article/Lutris-Pharma-Presents-Additional-Positive-Data-from-Its-Phase-2-Trial-of-LUT014-Gel-Demonstrating-Significant-Efficacy-in-Treating-Acneiform-Rash-Associated-with-Use-of-Anti-EGFR-Cancer-Therapies-at-the-ESMO-Gastrointestinal-Cancers-Congress-2025?storyId=686bdac2f3489e1d0abd1b3f